Table 2 KEGG pathway analysis of potential target genes functions
#term ID | term description | false discovery rate (p value) | matching proteins in your network (labels) | observed gene count |
|---|---|---|---|---|
hsa05215 | Prostate cancer | 4.06E-12 | NFKB1,MDM2,CDK2,IGF1R,EGFR,MAP2K1,HSP90AA1,AR,BCL2,FGFR1 | 10 |
hsa05224 | Breast cancer | 3.92E-08 | FGF2,IGF1R,EGFR,MAP2K1,PGR,ESR2,FGFR1,ESR1 | 8 |
hsa05218 | Melanoma | 1.35E-08 | MDM2,FGF2,IGF1R,EGFR,MITF,MAP2K1,FGFR1 | 7 |
hsa05212 | Pancreatic cancer | 1.40E-08 | NFKB1,EGFR,MAP2K1,TGFBR2,TGFBR1,MAPK8,VEGFA | 7 |
hsa05225 | Hepatocellular carcinoma | 1.11E-06 | IGF1R,EGFR,MAP2K1,TERT,GSTM1,TGFBR2,TGFBR1 | 7 |
hsa05220 | Chronic myeloid leukemia | 3.81E-07 | NFKB1,MDM2,MAP2K1,PTPN11,TGFBR2,TGFBR1 | 6 |
hsa05210 | Colorectal cancer | 5.77E-07 | EGFR,MAP2K1,TGFBR2,TGFBR1,MAPK8,BCL2 | 6 |
hsa05219 | Bladder cancer | 7.15E-07 | MMP2,MDM2,EGFR,MAP2K1,VEGFA | 5 |
hsa05222 | Small cell lung cancer | 1.98E-05 | NFKB1,CDK2,PTGS2,XIAP,BCL2 | 5 |
hsa05211 | Renal cell carcinoma | 0.00012 | MAP2K1,PTPN11,HIF1A,VEGFA | 4 |
hsa05214 | Glioma | 0.00015 | MDM2,IGF1R,EGFR,MAP2K1 | 4 |
hsa05203 | Viral carcinogenesis | 0.0036 | NFKB1,MDM2,CDK2,CHEK1 | 4 |
hsa05204 | Chemical carcinogenesis | 0.0031 | GSTM1, PTGS2, CYP1A1 | 3 |
hsa05216 | Thyroid cancer | 0.0119 | PPARG, MAP2K1 | 2 |
hsa05213 | Endometrial cancer | 0.0251 | EGFR, MAP2K1 | 2 |
hsa05221 | Acute myeloid leukemia | 0.0316 | NFKB1, MAP2K1 | 2 |
hsa05223 | Non-small cell lung cancer | 0.0329 | EGFR, MAP2K1 | 2 |